Physician profile

Eric Lloyd Jones

Internal Medicine · Virginia Beach, VA

NPI 1265462568

$428.55

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$78.05

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Alkermes, INC. $145.59 2021-2022
Mdd US Operations, LLC $72.84 2019
Indivior INC. $50.70 2024 Sublocade
Electronic Waveform Lab, INC. $29.51 2019
Braeburn INC. $27.35 2024 Brixadi
Biodelivery Sciences International, INC. $26.53 2019
Scilex Pharmaceuticals INC. $19.61 2019
Daiichi Sankyo INC. $16.45 2019
Otsuka America Pharmaceutical, INC. $15.25 2022
Kaleo, INC. $13.42 2019
Abbott Laboratories $11.30 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Eric Lloyd Jones

$428.55

in general payments reported 2019-2025

Years
2019-2024
Top company
Alkermes, INC.

https://glasscript.com/doctor/238309/eric-lloyd-jones

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.